Filtering

DOP26 Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

C.G. af Björkesten1, T. Ilus2, T. Hallinen3, E. Soini3, A. Eberl1, K. Hakala4, M. Heikura5, E. Hirsi6, A. Jussila2, M. Kellokumpu7, R. Koskela8, I. Koskinen9, V. Moilanen10, C. Nielsen11, U. Nieminen1, H. Nuutinen12, M. Heikkinen13, U.M. Suhonen14, J. Tillonen15, K. Utriainen16, I. Vihriälä17, C. Wennerström18,19, A. Borsi20, R. Nissinen21, M. Koivunen21, T. Sipponen1

1University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2Tampere University Hospital, Tampere, Finland, 3ESiOR Oy, Kuopio, Finland, 4Kanta-Häme Central Hospital, Hämeenlinna, Finland, 5North Karelia Central Hospital, Joensuu, Finland, 6South Karelia Central Hospital, Lappeenranta, Finland, 7Lapland Central Hospital, Rovaniemi, Finland, 8Oulu University Hospital, Oulu, Finland, 9Central Finland Central Hospital, Jyväskylä, Finland, 10Satakunta Central Hospital, Pori, Finland, 11Vaasa Central Hospital, Vaasa, Finland, 12Turku University Hospital, Turku, Finland, 13Kuopio University Hospital, Kuopio, Finland, 14Kainuu Central Hospital, Kajaani, Finland, 15Päijät-Häme Central Hospital, Lahti, Finland, 16Turku University Hospital Salo Hospital, Salo, Finland, 17Central Ostrobothnia Central Hospital, Kokkola, Finland, 18Janssen Cilag, Medical Affairs, Solna, Sweden, 19Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark, 20Janssen Cilag Limited, Emea Hemar, High Wycombe, UK, 21Medical Affairs, Janssen Cilag Oy, Espoo, Finland

DOP27 Transanal minimally invasive surgery (TAMIS): A novel approach for treatment of pouch failure

ECCO'20 Vienna

Year: 2020
Authors:

E. Van Praag BSc1, R. Hompes1, C. Buskens1, P. Tanis1, M. Duijvestein2, W. Bemelman1

1Department of Surgery, Amsterdam UMC-location AMC, Amsterdam, The Netherlands, 2Department of Gastroenterology and Hepatology, Amsterdam UMC-location AMC, Amsterdam, The Netherlands

DOP28 Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohn’s disease: A pilot serum proteomic analysis of the PANTS cohort

ECCO'20 Vienna

Year: 2020
Authors:

S. Lin1,2, N. Chanchlani1,2, B.M. Invergo3, M.W. Anderson3, H.M. Guay4, M. Reppell4, J.W. Butler4, J.R. Goodhand1,2, T. Ahmad1,2, N.A. Kennedy1,2, Exeter IBD Pharmacogenetics Research Group

1Exeter IBD Pharmacogenetics Research Group, University of Exeter, Exeter, UK, 2Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK, 3Translational Exchange @ Exeter- Living Systems Institute, University of Exeter, Exeter, UK, 4Department of Research and Development, AbbVie Inc., North Chicago, USA

DOP29 Elevation of a novel blood-based gene signature in a severe Crohn’s disease (CD) subtype preceding surgery defines and predicts a post-surgical decrease in pro-inflammatory pathway activation

ECCO'20 Vienna

Year: 2020
Authors:

R. Gonsky1, P. Fleshner2, G. Botwin1, E. Biener-Ramanujan1, D. McGovern1, S. Targan1

1Cedars Sinai Medical Center, Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California, USA, 2Cedars Sinai Medical Center, Department of Surgery, Los Angeles, CA, USA

DOP30 Multi-‘omics profiling in patients with quiescent inflammatory bowel disease identifies biomarkers predicting relapse

ECCO'20 Vienna

Year: 2020
Authors:

N. Borren1, D. Plichta2, A. joshi1, G. Bonilla3, R. Sadreyev3, H. Vlamakis2, R. Xavier1, A. Ananthakrishnan1

1Massachusetts General Hospital, Division of Gastroenterology, Boston, USA, 2Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, USA, 3Department of Molecular Biology, Massachusetts General Hospital, Boston, USA

DOP31 Serum protein markers for early and differential IBD diagnosis validated by machine learning approaches

ECCO'20 Vienna

Year: 2020
Authors:

S. Verstockt1,2, N. Verplaetse2,3, D. Raimondi3, B. Verstockt1,4, E. Glorieus5, M. De Decker6, L. Hannes2, V. Ballet4, E. Vandeput1, Y. Moreau3, M. Ferrante1,4, D. Laukens5, F. Mana6, M. De Vos5, S. Vermeire1,4, I. Cleynen2

1Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium, 2Laboratory for Complex Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium, 3Department of Electrical Engineering ESAT, KU Leuven, Leuven, Belgium, 4Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 5Department of Gastroenterology, University Hospital of Ghent, Ghent, Belgium, 6Department of Gastroenterology, University Hospitals Brussels, Brussels, Belgium

DOP32 Clinical and molecular characterisation of patients with durable response to ustekinumab induction therapy: Results from the UNIFI phase 3 studies in moderate-to-severe ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

K. Li, F. Yang, K. Hayden, D. Strawn, E. Wadman, S. Bhagat, C. Marano, J.R. Friednman

Janssen Research and Development- LLC, Immunology, Spring House, USA

DOP33 Stratification of patients for treatment with adalimumab by a combination of immune-profiling and in vivo efficacy studies in a novel mouse model of ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

R. Gropp1, H. Jodeleit1, J. Caesar1, C. Villarroel Aguilera1, S. Sterz2, L. Holdt2, F. Beigel3, S. Breiteneicher3, J. Stallhofer3, M. Siebeck1

1Hospital of the Ludwig Maximilian Universität, General, Visceral- und Transplantation Surgery, München, Germany, 2Hospital of the Ludwig Maximilian Universität, Institute of Laboratory Medicine, München, Germany, 3Hospital of the Ludwig Maximilian Universität, Department of Medicine II, München, Germany

DOP34 Transplantation of human intestine into the mouse: A novel platform for study of inflammatory enterocutaneous fistulas

ECCO'20 Vienna

Year: 2020
Authors:

R.S. Bruckner1, E. Nissim-Eliraz2, N. Marsiano2, E. Nir2, H. Shemesh2, M. Leutenegger1, C. Gottier1, S. Lang1, M.R. Spalinger1, S. Leibl3, G. Rogler1,4, S. Yagel5, M. Scharl1,4, N.Y. Shpigel2

1Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland, 2Department of Basic Sciences, Koret School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot, Israel, 3Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland, 4Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland, 5Department of Obstetrics and Gynecology, Hadassah University Hospital, Jerusalem, Israel

DOP35 Monitoring of mucosal T cells subsets under biotherapies in IBD: responders exhibit a phenotype similar to healthy controls

ECCO'20 Vienna

Year: 2020
Authors:

N. Hammoudi1, K. Perez1, D. Hassid1, M.L. Tran Minh1, J.M. Gornet1, C. Baudry1, N. Lourenco1, B. Gergaud2, V. Chardiny2, J. Bonnet1, L. Le Bourhis2, M. Allez1

1APHP Saint Louis, Gastroenterology, Paris, France, 2INSERM, Unité U1160, Paris, France

DOP36 Family-specific host genetic and gut microbial signatures have a beneficial role in early identification of familial inflammatory bowel diseases

ECCO'20 Vienna

Year: 2020
Authors:

G.Y. SHIN1, Y.M. Park1, E. Ha2, K.N. Gu2, K. Kim2, C.K. Lee1, H.J. Kim1

1Department of Gastroenterology, Center for Crohn’s and Colitis, Kyung Hee University College of Medicine, Seoul, Korea Republic of, 2Department of Biology, Kyung Hee University College of Sciences, Seoul, Korea Republic of

DOP37 Neoplastic lesions outside diseased area in inflammatory bowel disease patients: A national cohort study

ECCO'20 Vienna

Year: 2020
Authors:

A. Cremer1, P. Demetter2, M. De Vos3, J.F. Rahier4, F. Baert5, T. Moreels6, E. Macken6, E. Louis7, S. Vermeire8, D. Franchimont1, Belgian Inflammatory Bowel Disease Research and Development (BIRD) Group

1Department of Gastroenterology, Erasme University Hospital- ULB, Brussels, Belgium, 2Institut Jules Bordet, Department of Pathology, Brussels, Belgium, 3Department of Gastroenterology, University Hospital Ghent, Ghent, Belgium, 4Department of Gastroenterology, CHU UCL Namur, Yvoir, Belgium, 5Department of Gastroenterology, AZ Delta, Roeselare, Belgium, 6Department of Gastroenterology, University Hospital Antwerp, Edegem, Belgium, 7Department of Gastroenterology, University Hospital Liège, Liège, Belgium, 8Department of Gastroenterology, University Hospital Leuven, Leuven, Belgium

DOP38 Prevalence of fatigue in a severe inflammatory bowel disease cohort highly exposed to biologics

ECCO'20 Vienna

Year: 2020
Authors:

C. Liefferinckx1,2, M. El hamdi1, M. Fassin2, A. Cremer1,2, C. Minsart1,2, L. Amininejad1, V. Wambacq1, A. Van Gossum1, D. Franchimont1,2

1Department of Gastroenterology, Hopital Erasme, Brussels, Belgium, 2Laboratory of Experimental Gastroenterology, ULB, Brussels, Belgium

DOP39 The first prospective, multicentre, randomised controlled trial on discontinuation of infliximab in ulcerative colitis in remission; endoscopic normalisation does not guarantee successful withdrawal

ECCO'20 Vienna

Year: 2020
Authors:

T. Kobayashi1, S. Motoya2, S. Nakamura3, T. Yamamoto4, M. Nagahori5, S. Tanaka6, T. Hisamatsu7, F. Hirai8, H. Nakase9, K. Watanabe10, T. Matsumoto11, M. Tanaka12, T. Abe13, Y. Suzuki14, M. Watanabe5, T. Hibi1, HAYABUSA

1Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, Tokyo, Japan, 2IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan, 3Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Nishinomiya, Japan, 4Yokkaichi Hazu Medical Centre, IBD Centre, Yokkaichi, Japan, 5Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan, 6Department of Endoscopy and Medicine, Hiroshima University, Hiroshima, Japan, 7Department of Gastroenterology and Hepatology, School of Medicine, Kyorin University, Mitaka, Japan, 8Department of Gastroenterology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, 9Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan, 10Department of Intestinal Inflammation Research, Hyogo College of Medicine, Nishinomiya, Japan, 11Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan, 12Department of Pathology, Hirosaki Municipal Hospital, Morioka, Japan, 13Department of Data Science, Yokohama City University, Yokohama, Japan, 14IBD Center, Toho University Sakura Medical Center, Sakura, Japan

DOP40 Does levels of concerns and expectations predict IBD disease status?

ECCO'20 Vienna

Year: 2020
Authors:

V. Pittet, Swiss IBD Cohort Study

Center for Primary Care and Public Health, University of Lausanne, Epidemiology and Health Services, Lausanne, Switzerland

DOP41 Low-grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century: A large multi-centre retrospective cohort study

ECCO'20 Vienna

Year: 2020
Authors:

M. Kabir1,2, K. Curtius3, I. Al-Bakir2,3,4, J. Hartono5, M. Johnson6, J.E. East6, J.O. Lindsay7,8, R. Vega9, S. Thomas-Gibson1,2, A. Hart2,4, T. Graham3, A. Wilson1,2

1Wolfson Endoscopy Unit, St Mark’s Hospital, London, UK, 2Division of Surgery and Cancer, Imperial College London, London, UK, 3Barts Cancer Institute, Queen Mary University of London, London, UK, 4Inflammatory Bowel Diseases Unit, St Mark’s Hospital, London, UK, 5Gastroenterology Department, National University Hospital, Singapore, 6Translational Gastroenterology Unit, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK, 7Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UK, 8Barts and the London School of Medicine and Dentistry, Centre for Immunobiology, Queen Mary University of London, London, UK, 9Endoscopy Unit, University College London Hospital, London, UK

DOP42 Impact of discontinuing thiopurines at anti-TNF initiation in inflammatory bowel disease: A nationwide Danish cohort study

ECCO'20 Vienna

Year: 2020
Authors:

S. Bohn Thomsen1, R. Ungaro2, K. Allin3, G. Poulsen1, A. Mikael1, J.F. Colombel2, T. Jess1

1Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark, 2Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA, 3Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

DOP43 The risk of extra-intestinal cancer in inflammatory bowel disease (IBD): A systematic review and meta-analysis of population-based cohort studies

ECCO'20 Vienna

Year: 2020
Authors:

B.Z.S. Lo, M. Zhao, I. Vind, J. Burisch

Copenhagen University Hospital Hvidovre, The Gastrounit, Hvidovre, Denmark

DOP44 Cancer risk in a high-incidence inflammatory bowel disease population: a Faroese IBD cohort study

ECCO'20 Vienna

Year: 2020
Authors:

J.M.M. Midjord1, A.G. Vang2, T. Hammer3, J. Burisch1, K.R. Nielsen1, The Faroese IBD Study Group

1Medical Department, National Hospital of the Faroe Islands, Torshavn, Faroe Islands, 2Department of Health and Nursing Sciences, University of the Faroe Islands, Torshavn, Faroe Islands, 3Department of Occupational Medicine and Public Health, The Faroese Hospital System, Torshavn, Faroe Islands

DOP45 Increased prevalence but not incidence of myocardial infarction and stroke in patients with inflammatory bowel diseases in Quebec in 1996–2015

ECCO'20 Vienna

Year: 2020
Authors:

C. Verdon1, J. Reinglas1, C. Filliter1, J. Coulombe1, L. Gonczi2, W. Afif1, G. Wild1, E. Seidman1, A. Bitton1, T. Bessissow1, P. Brassard1, P.L. Lakatos PhD1,2

1Division of Gastroenterology, McGill University, Montreal, Canada, 2Department of Medicine I, Semmelweis University, Budapest, Hungary